A Wild-Type of Approach in the First-line Treatment of HRD-Positive Advanced Ovarian Cancer

This activity is part of a series


Richard T. Penson, MD, MRCP
Physician at Mass General Brigham
Associate Professor Harvard Medical School
Institutional Review Board (IRB) Chair
Dana Farber Harvard Cancer Center
Boston, MA
Richard T. Penson, MD, MRCP

Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.

Ramez N. Eskander, MD
Clinical Professor of Gynecologic Oncology
Clinical Trial Office Director for Oncology
University of California San Diego Health and Rebecca & John Moores Cancer Center
Co-Director, UC San Diego Health International Patient Program
La Jolla, CA

Statement of Need

Data from recent clinical trials for first-line combination options using immunotherapies for ovarian cancer (OC) can be challenging for clinicians with no experience selecting patients for combinatorial treatment approaches or using combination therapies for their patients.  During this podcast, Drs. Richard Penson and Ramez Eskander will educate clinicians on the use of immune checkpoint inhibitors for the treatment of OC and the use of biomarker analyses to optimize patient selection.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Evaluate the utility of emerging first-line treatment approaches for HRD-positive (non-BRCA) OC

Financial Support

Supported by a joint educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Primary Audiences: Medical oncologists, gynecologic oncologists, physician assistants (PAs), nurses, nurse practitioners (NPs), and pharmacists working in oncology settings

Secondary Audiences: Gynecologists and primary care physicians (PCPs)

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-013-H01-P).

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 03/28/2025. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Dr. Eskander reports the following financial relationships:

Advisory Board: AstraZeneca; CARIS Life Sciences; Clovis Oncology; Daiichi Sankyo; GSK; ImmunoGen, Inc.; Myriad Genetics, Inc.; PMV Pharmaceuticals, Inc.; Regeneron Pharmaceuticals Inc.; and Seagen Inc.

Other Financial or Material Support: Advisor with GOG Partners / GOG Foundation

The following individuals have no financial relationships to disclose: 

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Thomas Mitchell (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD  (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


A Wild-Type of Approach in the First-line Treatment of HRD-Positive Advanced Ovarian Cancer
Event Date: 03/28/2024